Citations

Clear

1446 citation(s) found for "Howard, F".

Response to Letter to the Editor From Zhang et al: “Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer”
Konda, Bhavana , Sherman, Eric J. , Ryder, Mabel , Agulnik, Mark , Handley, Demond , Moses, Catherine, Jacob, Rajani, Streicher, Howard , Shah, Manisha H. , Streicher, Howard , Ryder, Mabel , Massarelli, Erminia , Nieva, Jorgé , Muzaffar, Jameel, Morris, John C, Ho, Alan L. , Wei, Lai , Moses, Catherine, Jacob, Rajani, Wright, John, Carson, William E.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 4, 2025 | Volume: 110 | Issue: 7 | Pages: e2425-e2426

10.1210/clinem/dgaf221 | PMID 40184489 Get It

Multicenter analysis of flow diversion for recurrent/persistent intracranial aneurysms after stent-assisted coiling
Salem, Mohamed M. , Helal, Ahmed , Gajjar, Avi A. , Sioutas, Georgios S. , Heiferman, Daniel M. , Lylyk, Iván , Levine, Alex, Salih, Mira , Abbas, Rawad , Saber, Hamidreza , Lanzino, Giuseppe, Brinjikji, Waleed , Tanweer, Omar , Spiotta, Alejandro M , Park, Min S. , Dumont, Aaron S. , Kim, Louis J. , Kan, Peter , Wolfe, Stacey Q , Raz, Eytan , Shapiro, Maksim , Siddiqui, Adnan H. , Ares, William J. , Ogilvy, Christopher S. , Srinivasan, Visish M. , Starke, Robert M., Ducruet, Andrew F. , Tjoumakaris, Stavropoula , Jankowitz, Brian T. , Albuquerque, Felipe C , Nelson, Peter Kim , Riina, Howard A. , Lylyk, Pedro , Jabbour, Pascal , Burkhardt, Jan Karl, Heiferman, Daniel M , Lylyk, Ivan , Desai, Sohum , Borg, Nicholas , Brinjikji, Waleed , Spiotta, Alejandro M , Arthur, Adam Stephen , Levitt, Michael R , Kan, Peter , Hassan, Ameer E , Wolfe, Stacey Quintero , Raz, Eytan , Siddiqui, Adnan H , Ares, William J , Ogilvy, Christopher S , Tjoumakaris, Stavropoula , Jankowitz, Brian , Albuquerque, Felipe C , Jabbour, Pascal , Burkhardt, Jan‐Karl , Naamani, Kareem El , Renieri, Leonardo , Monteiro, Andre , Abdelsalam, Ahmed, Catapano, Joshua S , Lanzino, Giuseppe , Kim, Louis J. , Levitt, Michael R. , Hassan, Ameer E , Limbucci, Nicola , Colby, Geoffrey P. , Hanel, Ricardó A. , Levy, Elad I. , Thomas, Ajith J , Lopes, Demetrius K.

Mayo Clinic

Journal of NeuroInterventional Surgery | March 27, 2025 | Volume: 18 | Issue: 2 | Pages: 324-331

10.1136/jnis-2024-022422 | PMID 40139781 Get It

Background Flow-diverter stents (FDS) have become the standard of care for a wide range of intracranial aneurysms, but their efficacy/safety in the context of recurrent/recanalized aneurysms following stent-assisted coiling (SAC) is not well established. We evaluate the outcomes of FDS retreatment in a large multicenter cohort. Methods We retrospectively analyzed data from 118 patients across 22 institutions who underwent FDS retreatment for recurrent/persistent aneurysms after SAC (2008–22). The primary outcome was angiographic occlusion status at last follow-up, categorized as complete (100%), near-complete (90–99%), or incomplete (<90%) occlusion. Secondary outcomes included procedural complications and clinical outcomes measured by the modified Rankin Scale (mRS). Results A total of 118 patients (median age 57, 74.6% female) with median follow-up of 15.3 months were identified. Complete occlusion was achieved in 62.5% and near-complete occlusion in 25%. FDS deployment within the pre-existing stent was successful in 98.3% of cases. Major complications occurred in 3.4% of cases, including postoperative aneurysmal rupture with resultant mortality (1.6%) and thromboembolic events with long-term disability (1.6%). Favorable clinical outcomes (mRS 0–2) were observed in 95.1% of patients. Wider aneurysm neck diameter was a significant predictor of incomplete occlusion (adjusted OR (aOR) 1.23 per mm, P=0.044), with male sex trending towards association with non-occlusion (aOR 3.2, P=0.07), while baseline hypertension was associated with complete occlusion (aOR 0.32, P=0.048). Conclusions FDS treatment for recurrent/residual aneurysms after SAC represents a viable treatment option for these challenging cases with acceptable safety and reasonable occlusion rates, although lower than de novo FDS occlusion rates.
Demographic and Clinical Factors Associated With SARS-CoV-2 Anti-Nucleocapsid Antibody Response Among Previously Infected US Adults: The C4R Study
Demmer, Ryan T. , Wu, Christina , Sun, Yifei , Cushman, Mary , Boyle, Rebekah, Styer, Linda M. , Bell, Taison D., Anderson, Michaela R. , Schreiner, Pamela J. , Bowler, Russell, Rock, Jean M., Bievenue, Rachel, Kandula, Namratha R. , Raffield, Laura M. , Elkind, Mitchell S.V. , Ortega, Victor E. , Woodruff, Prescott G. , Oelsner, Elizabeth C. , Wu, Chaoqi , Anderson, Michaela R , Lee, Joyce S , Xanthakis, Vanessa , Pirzada, Amber , Mantis, Nicholas J , Raffield, Laura M , Oelsner, Elizabeth C , Demmer, Ryan T , Kim, John S. , Balte, Pallavi , Tracy, Russell P. , Allen, Norrina B. , Schwartz, David A. , Lee, Joyce , Xanthakis, Vanessa , Doyle, Margaret F. , Regan, Elizabeth Anne , Make, Barry J. , Kanaya, Alka M , Wenzel, Sally E. , Coresh, Josef , Isasi, Carmen R. , Howard, Virginia J. , Cole, Shelley A. , Henderson, Joel

Mayo Clinic

Open Forum Infectious Diseases | March 20, 2025 | Volume: 12 | Issue: 3 | Pages: No page available

10.1093/ofid/ofaf123 | PMID 40124199 Get It

Abstract Despite the availability of effective vaccines and a recent decrease in annual deaths, COVID-19 remains a leading cause of death. Serological studies provide insights into host immunobiology of adaptive immune response to infection, which holds promise for identifying high-risk individuals for adverse COVID-19 outcomes. We investigated correlates of anti-nucleocapsid antibody responses following SARS-CoV-2 infection in a US population-based meta-cohort of adults participating in longstanding National Institutes of Health–funded cohort studies. Anti-nucleocapsid antibodies were measured from dried blood spots collected between February 2021 and February 2023. Among 1419 Collaborative Cohort of Cohorts for COVID-19 Research participants with prior SARS-CoV-2 infection, the mean age (standard deviation) was 65.8 (12.1), 61% were women, and 42.8% self-reported membership in a race/ethnicity minority group. The proportion of participants reactive to nucleocapsid peaked at 69% by 4 months after infection and waned to only 44% ≥12 months after infection. Higher anti-nucleocapsid antibody response was associated with older age, Hispanic or American Indian Alaskan Native (vs White) race/ethnicity, lower income, lower education, former smoking, and higher anti-spike antibody levels. Asian race (vs White) and vaccination (even after infection) were associated with lower nucleocapsid reactivity. Neither vaccine manufacturer nor common cardiometabolic comorbidities were not associated with anti-nucleocapsid response. These findings inform the underlying immunobiology of adaptive immune response to infection, as well as the potential utility of anti-nucleocapsid antibody response for clinical practice and COVID-19 serosurveillance.
TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation and Fibrosis Improve with Treatment
Osterhout, Robin , Channick, Richard, Frantz, R, McLaughlin, V.V., Vachiéry, J, Roscigno, Robert F., Mottola, David, Sitapara, Ravi, Aranda, R., Zisman, Lawrence S. , Bruey, Jean‐Marie, Zamanian, R.T., Ghofrani, Hossein Ardeschir , Osterhout, Robin E. , Benza, Raymond L. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier , Sitapara, Ravikumar

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804783 Get It

Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Zolty, R., Kingrey, J.F. , Penn, Benjamin G., Sobol, Irina , Sood, Namita , Benza, R.L., Channick, Richard, Frantz, R, McLaughlin, V.V., Vachiéry, J, Zamanian, R.T., Cravets, Matt , Roscigno, Robert F., Mottola, David, Parsley, Ed, Aranda, R., Zisman, Lawrence S. , Ghofrani, Hossein Ardeschir , Sahay, Sandeep , Subías, Pilar Escribano , Penn, B, Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804612 Get It

Trial in Progress: PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension (PAH)
Held, Matthias , Benza, R.L., Channick, Richard, Chin, K. , Frantz, R, Howard, L, McLaughlin, Vallerie V. , Zamanian, R.T., Bruey, Jean‐Marie, Cravets, Matt , Mottola, David, Zisman, Lawrence S. , Parsley, Ed, Roscigno, Robert F., Aranda, R., Vachiéry, J, Sitbon, Olivier , Frantz, Robert P. , Ghofrani, Hossein Ardeschir , Hemnes, Anna R. , McLaughlin, Vallerie V.

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804609 Get It

Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).
Roy, Soumyajit , Eastham, James A., Beltran, Himisha , Kishan, Amar U. , Jia, Angela Y. , García, Jorge A. , McKay, Rana R. , Sartor, Alton Oliver, Halabi, Susan , Feng, Felix Y. , Halabi, Susan , Sun, Yilun , Gleave, Martin , Zaorsky, Nicholas G. , Small, Eric J. , Nguyen, Paul L. , Attard, Gerhardt , Rosenthal, Seth A. , Morris, Michael J. , Sandler, Howard M. , Spratt, Daniel E.

Mayo Clinic

Journal of Clinical Oncology | February 18, 2025 | Volume: 43 | Issue: 5_suppl | Pages: 309-309

10.1200/jco.2025.43.5_suppl.309 Get It

309 Background: Standard of care (SOC) treatment options for HR-PCa include RT with long-term androgen deprivation (LT-ADT) or RP with selective use of post-operative RT +/- androgen deprivation therapy (ADT). The optimal treatment approach has been assessed in retrospective population-based and multi-center comparisons, which have yielded mixed results with substantial bias. Therefore, we conducted an emulated randomized comparison of RT vs RP in HR-PCa leveraging patients enrolled in RCTs. Methods: We searched Medline for RCTs in HR-PCa with a SOC arm of an RT- or RP-based regimen. Inclusion required similar experimental treatment and contemporaneous enrollment in the same country to reduce bias. This identified 2 trials, NRG/RTOG 0521 (RT+LT-ADT +/- 6 cycles docetaxel [doce]), and CALGB 90203 (RP +/- neoadjuvant 6 cycles doce and ADT). Due to inherent difference in the biochemical recurrence criteria after RT vs RP, we chose inverse probability of treatment weighted (IPTW) cumulative incidence of distant metastasis (DM) as the primary endpoint, considering deaths as competing events. Death after DM was measured to create a harmonized metric of deaths likely attributed to PCa. To assess potential residual selection bias, death without DM to capture non-cancer associated deaths was analyzed. Results: Overall, 1290 patients (RT n=557, RP n=733) were included, with similar median follow-up of 6.4 years. Prior to IPTW, RP patients were significantly younger with lower baseline PSA compared to RT patients. Adjuvant (18%) and salvage therapy (44%) was used in RP cohort. Cumulative incidence of DM was significantly lower in patients who underwent RT compared to RP (8-year DM: 16% vs 23%; p=0.01; subdistribution hazard ratio [sHR] 0.48 [95%CI 0.34-0.69], p<0.001). 8-year rates of death after DM were 10% vs 8% (p=0.72) in the RP and RT patients, respectively. RT patients had significantly greater risk of death without DM (HR 2.09 [1.01-4.34], p=0.048) with early differences measured. On a cross-arm comparison, 8-year cumulative incidence of DM when comparing SOC RT+LT-ADT group versus the doce+ADT+RP group was 18% vs 21%, respectively (sHR 0.75 [0.45-1.24], p=0.26). Conclusions: HR-PCa patients enrolled on RCTs had significantly lower incidence of DM with an RT-based strategy compared to an RP-based approach. Longer follow-up is needed to assess deaths attributed to PCa. Despite the strengths of the comparison (use of cooperative group RCT data, contemporaneous enrollment in the same country, patients fit enough for chemotherapy, and IPTW adjustments) there appears to be residual unmeasured bias, as expected, based on greater early deaths without DM in the RT arm. Utilization of post-operative radiotherapy and ADT+Doce may mitigate differences between RP and SOC RT+LT-ADT.
Outcomes of arteriovenous malformation patients with multiple versus single feeders: A multicenter retrospective study with propensity-score matching
Musmar, Basel , Adeeb, Nimer , Abdalrazeq, Hammam , Tjoumakaris, Stavropoula I, Salim, Hamza , Kondziolka, Douglas, Sheehan, Jason P. , Ogilvy, Christopher S. , Riina, Howard A. , Naamani, Kareem El, Ironside, Natasha , Ataoglu, Cagdas , Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Erginoğlu, Ufuk , Sen, Rajeev , Griessenauer, Christoph J., Burkhardt, Jan-Karl, Starke, Robert M., Başkaya, Mustafa K. , Levitt, Michael R, Altschul, David , McAvoy, Malia , Aslan, Assala , Abushehab, Abdallah, Swaid, Christian, Abla, Adib A. , Sizdahkhani, Saman , Koduri, Sravanthi , Atallah, Elias , Karadimas, Spyridon, Gooch, M Reid, Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M. , Cochran, Joseph, Pukenas, Bryan , Smith, Edward, Patel, Aman B. , Cuellar, Hugo H, Lawton, Michael T. , Guthikonda, Bharat , Ogilvy, Christopher S. , Alaraj, Ali , Smith, Edward R. , Salim, Hamza , Essibayi, Muhammed Amir , Alwakaa, Omar , Mosimann, Pascal J , Jabbour, Pascal , Alaraj, Ali , Abla, Adib , Altschul, David J , Musmar, Basel , Ogilvy, Christopher S , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Burkhardt, Jan‐Karl , Roy, Joanna M. , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Rezai, Arwin, Tos, Salem M , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Sekhar, Laligam N. , Karadimas, Spyridon K. , Gooch, Michael Reid , Chen, Peng R , Blackburn, Spiros , Choudhri, Omar , Orbach, Darren B. , Aziz‐Sultan, Mohammad Ali , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

European Stroke Journal | February 15, 2025 | Volume: 10 | Issue: 3 | Pages: 946-960

10.1177/23969873251319924 | PMID 39953956 Get It

Abstract Introduction The impact of multiple feeding arteries on clinical outcomes of cerebral arteriovenous malformations (AVMs) is not well understood. This study aims to compare outcomes between AVMs with multiple versus single feeding arteries. Patients and Methods Data from the Multicenter International Study for Treatment of Brain AVMs (MISTA) consortium were analyzed. Propensity score matching (PSM) was used to balance cohorts. Subgroup analysis was conducted for ruptured and unruptured AVMs and different treatment options, and multivariable logistic regression was applied to assess the impact of feeding artery origin. Results Among 953 patients, 661(69.4%) had multiple feeding arteries, and 292 (30.6%) had a single feeding artery. After PSM, which included 422 matched patients (211 in each group), the differences in obliteration rates (68.7% vs 74.8%, OR 0.73, 95% CI: 0.48–1.12, p = 0.16) and symptomatic complications (15.6% vs 11.8%, OR 1.37, 95% CI: 0.78–2.41, p = 0.25) were not significant. Subgroup analysis comparing ruptured and unruptured AVMs and different treatment options showed no significant differences across all subgroups. Multivariable analysis identified PICA feeders as significantly associated with increased odds of all complications (OR 7.33, 95% CI: 2.14–25.1, p = 0.002). Discussion and Conclusion AVMs with a single feeding artery were more likely to present with rupture, but no significant differences in obliteration rates or complications were observed between the groups after PSM. These findings suggest that while the number of feeding arteries may influence the initial presentation, it does not appear to impact overall treatment success or patient prognosis. Further prospective studies are needed to confirm these findings.
Comparative outcomes of arteriovenous malformations treatment in eloquent versus non-eloquent brain: A multicenter study with propensity-score weighting
Adeeb, Nimer , Abdalrazeq, Hammam , Salim, Hamza , Aslan, Assala , Tjoumakaris, Stavropoula I, Ogilvy, Christopher S. , Başkaya, Mustafa K. , Kondziolka, Douglas, Sheehan, Jason P. , Riina, Howard A. , Abushehab, Abdallah, Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Ataoglu, Cagdas , Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Park, Min S. , Erginoğlu, Ufuk , Sen, Rajeev , Griessenaur, Christoph, Burkhardt, Jan‐Karl , Starke, Robert M., Sekhar, Laligam N., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Zeineddine, Hussein A. , Abla, Adib A. , Atallah, Elias , Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew, Srinivasan, Visish M. , Bulsara, Ketan R., Kim, Louis J. , Pukenas, Bryan , Smith, Edward R. , Alaraj, Ali , Patel, Aman B. , Notarianni, Christina , Lawton, Michael T. , Guthikonda, Bharat , Salim, Hamza , Dmytriw, Adam A , Levitt, Michael R , Chen, Peng R , Alaraj, Ali , Guthikonda, Bharat , Jabbour, Pascal , Abla, Adib , Altschul, David J , Ogilvy, Christopher S , Alwakaa, Omar , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Burkhardt, Jan‐Karl , Musmar, Basel , Roy, Joanna M. , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Mantziaris, Georgios , Hanalıoğlu, Şahin , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Sekhar, Laligam N. , Levitt, Michael R. , Gooch, Michael Reid , Koch, Matthew J. , Blackburn, Spiros , Kim, Louis J. , Choudhri, Omar , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Savardekar, Amey Rajan , Cuellar, Hugo , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

International Journal of Stroke | February 14, 2025 | Volume: 20 | Issue: 7 | Pages: 852-863

10.1177/17474930251323503 | PMID 39948730 Get It

Background: Arteriovenous malformations (AVMs) are complex vascular anomalies with a high risk of hemorrhage and neurological deficits, especially when located in eloquent brain regions. The eloquence of an AVM location is a critical factor in the treatment planning, influencing both the risk of complications and long-term functional outcomes. This study aims to compare outcomes between eloquent and non-eloquent AVMs. Methods: This multicenter, retrospective study utilized data from the Multicenter International Study for Treatment of Brain AVMs (MISTA) consortium. Patients with eloquent and non-eloquent AVMs were compared on baseline characteristics, angiographic outcomes, and functional outcomes using the modified Rankin Scale (mRS). Propensity score weighting (IPTW) was applied to adjust for confounding variables. Results: The study included 1013 patients, with 498 (49.2%) AVMs located in eloquent regions and 515 (50.8%) in non-eloquent regions. In unadjusted analysis, eloquent AVMs had lower complete obliteration rates (67.6% vs 79.5%, OR: 0.53, 95% CI: 0.39–0.72, p < 0.001) and higher complication rates (24.5% vs 19.0%, OR: 1.38, 95% CI: 1.02–1.86, p = 0.03) compared to non-eloquent AVMs. After IPTW adjustment, eloquent AVMs continued to show significantly higher odds of overall complications (OR: 1.68, 95% CI: 1.12–2.52, p = 0.01) and symptomatic complications (OR: 1.77, 95% CI: 1.12–2.80, p = 0.01). Secondary analysis within the eloquent group indicated that embolization was linked to an elevated risk of complications. Surgery and radiosurgery showed comparable functional outcomes at last follow-up and complications rates with higher complete obliteration rates in surgery. Conclusion: AVMs in eloquent brain areas present higher risks of complications and lower obliteration rates, emphasizing the need for cautious, individualized treatment planning. Within the eloquent group, embolization increased the risk of complications, while surgery and radiosurgery showed comparable functional outcomes at last follow-up and complication rates with higher complete obliteration rates in surgery. These findings highlight the importance of location in AVM management and support further research focusing on comparing treatment strategies for AVMs in eloquent brain areas.